Red and Near-Infrared Light Therapy: Mitochondrial Mechanisms and Thyroid Outcomes

What photobiomodulation is

Photobiomodulation (PBM), commonly marketed as red light therapy, is the use of low-power red (roughly 600–700 nm) and near-infrared (roughly 780–1,070 nm) light to influence cellular function. Unlike surgical lasers, the intent is not to heat or ablate tissue. The doses used are non-thermal, and the effect is biochemical rather than mechanical.

Wavelength matters because it determines penetration depth. Red light in the 630–670 nm range is largely absorbed in skin and superficial tissue. Near-infrared light around 810–850 nm passes further, reaching muscle, joint, and — depending on delivery — the shallow anterior structures of the neck, including the thyroid gland, which sits only a few millimeters below the surface.

The mitochondrial mechanism

The most supported mechanism centers on cytochrome c oxidase (complex IV of the electron transport chain), which contains copper and heme centers that absorb red and near-infrared photons. Under metabolic stress, nitric oxide can bind competitively at these centers and inhibit electron flow. Photon absorption is thought to displace that bound nitric oxide, restoring oxygen consumption and increasing ATP output.

Two secondary consequences follow. Released nitric oxide acts locally as a vasodilator, transiently increasing perfusion to the treated tissue. And the brief, controlled rise in mitochondrial reactive oxygen species acts as a hormetic signal, activating redox-sensitive transcription factors such as NF-κB and Nrf2 that upregulate antioxidant enzymes, heat shock proteins, and repair pathways. This is why PBM effects are described as dose-dependent and biphasic: too little does nothing, and too much can suppress the very response being sought.

Why the thyroid is a plausible target

The thyroid is unusual among endocrine organs in being both superficial and metabolically demanding. Thyroid hormone synthesis requires hydrogen peroxide generated by dual oxidase enzymes at the apical membrane of follicular cells, which means healthy thyroid tissue operates under a constant oxidative load and depends heavily on local antioxidant capacity, including selenium-dependent glutathione peroxidases.

In Hashimoto's thyroiditis, autoimmune lymphocytic infiltration compounds that oxidative burden and progressively destroys functional follicular tissue. The theoretical case for PBM is that improving mitochondrial function and antioxidant signaling in surviving follicular cells could preserve residual hormone output — a tissue-preservation argument rather than a claim to reverse autoimmunity.

What the clinical trials found

The strongest human data come from a Brazilian research group led by Höfling and colleagues. In a randomized, placebo-controlled trial, adults with hypothyroidism secondary to chronic autoimmune thyroiditis received ten sessions of near-infrared (830 nm) low-level laser therapy applied over the thyroid, or placebo. At nine months of follow-up, the treated group required significantly lower doses of levothyroxine, and a subset were able to discontinue replacement entirely, while the placebo group was unchanged (Höfling et al., Lasers in Surgery and Medicine, 2013).

The same cohort showed reductions in anti-thyroid peroxidase antibody levels and improved thyroid parenchymal echogenicity on ultrasound, suggesting a structural rather than purely biochemical change. A separate six-year follow-up of treated patients reported that a meaningful fraction maintained reduced hormone requirements long-term, though attrition and the absence of a maintained control arm limit what can be concluded.

Outside the thyroid, the evidence base is broader and more consistent: randomized trials support PBM for reducing exercise-induced muscle fatigue and soreness, accelerating wound healing, and improving symptoms in oral mucositis, which is one of the few indications with formal clinical guideline endorsement.

How we read the evidence

The mechanism is well characterized and biologically coherent. The thyroid-specific outcome data are genuinely promising but come from a small number of trials, largely from one research group, using clinical-grade laser devices with specified wavelength, power density, and per-point energy dose. Those parameters are not interchangeable with consumer LED panels, which differ substantially in irradiance and spectral output.

The practical reading: red and near-infrared light is a low-risk intervention with a plausible mechanism and encouraging early thyroid data that has not yet been replicated at scale. It should be treated as adjunctive. Nobody with hypothyroidism should reduce or stop levothyroxine on the basis of light therapy without supervised lab monitoring, since under-replacement carries real cardiovascular and cognitive consequences.